Results 1 to 10 of about 1,862 (151)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives

Journal of the American Heart Association, 2021
Cangrelor is the only currently available intravenous platelet P2Y12 receptor inhibitor. It is characterized by potent, predictable, and rapidly reversible antiplatelet effects.
Leonardo De Luca, Philippe Gabriel Steg
exaly   +3 more sources

Use of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting [PDF]

JACC: Advances
Background: Little is known about the use of cangrelor in patients with acute myocardial infarction (AMI) undergoing coronary artery bypass grafting (CABG).
Jennifer A. Rymer, MD, MBA, MHS, Courtney Page, MA, Brooke Alhanti, PhD, Cayla Pichan, MD, Aman Kansal, MD, Deepak L. Bhatt, MD, MPH, MBA, Ajar Kochar, MD, MHS, Dominick J. Angiolillo, MD, PhD, Miguel Diaz, MD, Neil J. Wimmer, MD, MSc, Lawrence Ang, MD, Richard Bach, MD, Ronald Jenkins, MD, Leo Brothers, MPH, W. Schuyler Jones, MD, Jeffrey B. Washam, PharmD, Tracy Y. Wang, MD, MHS, MSc, Dennis I. Narcisse, MD, Mir B. Basir, DO, Abhishek Chaturvedi, MD, Ron Waksman, MD   +20 more
doaj   +2 more sources

Cangrelor Use Patterns and Transition to Oral P2Y 12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry

Journal of the American Heart Association, 2022
Background In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention–related ischemic complications without increasing major bleeding.
Jennifer A Rymer, Dominick J Angiolillo, Laura Edwards   +2 more
exaly   +3 more sources

Oral P2Y12 inhibitors only versus cangrelor in critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: Oral P2Y12 inhibitors (P2Y12i) may have reduced efficacy in critically ill patients undergoing Impella-supported PCI. The intravenous P2Y12i cangrelor offers rapid and reversible platelet inhibition, but its role in this setting remains ...
Chiara Schaffner, Yanick Spahr, Alessandro Spirito, Gregorio Tersalvi, Irena Majcen, Firat Erdogan, Yuan Zhi, Armin Spahr, Thomas Seiler, Adrian Attinger, Florim Cuculi, Matthias Bossard   +11 more
doaj   +2 more sources

Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators’ viewpoint [PDF]

Cardiology Journal
According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).
Jacek Kubica, Piotr Adamski, Robert Gajda, Aldona Kubica, Małgorzata Ostrowska, Gavino Casu, Diana A. Gorog, Paul A. Gurbel, Tomasz Hajdukiewicz, Miłosz Jaguszewski, Young-Hoon Jeong, Agata Kosobucka-Ozdoba, Zuzana Motovska, Piotr Niezgoda, Maciej Piasecki, Przemysław Podhajski, Paolo Raggi, Uzeyir Rahimov, Jolanta M. Siller-Matula, Grzegorz Skonieczny, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Eliano P. Navarese   +23 more
doaj   +2 more sources

Cangrelor Bridge for Repeat Cesarean After Third Trimester Percutaneous Coronary Intervention for Total Occlusion NSTEMI [PDF]

Clinical Case Reports
Acute coronary syndrome is an uncommon but potentially life‐threatening complication in pregnancy, and dual antiplatelet therapy presents challenges in patients requiring cesarean delivery.
Vidya N. Mullangi, Sara Folk, Sneha Sharma, Gillian Belnavis, Shea Macielak, Danielle Blais, Talal Attar, Blair Suter, William H. Marshall V   +8 more
doaj   +2 more sources

The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention [PDF]

ClinicoEconomics and Outcomes Research
Bhavik Modi,1 Rob Cain,2 Richard Stork,2 Caroline Barwood,3 Gina Tarpey,2 Alessia Colucciello4 1Cardiac Surgery Department, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK; 2Chiesi Ltd, Manchester, UK; 3FIECON Ltd, London ...
Modi B, Cain R, Stork R, Barwood C, Tarpey G, Colucciello A   +5 more
doaj   +2 more sources

Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions [PDF]

Pharmaceuticals
The use of antiplatelet agents is essential in percutaneous coronary interventions, both periprocedurally and in the post-interventional period. Procedural antiplatelet therapy, aiming to limit ischemic complications, is mostly administered with oral ...
Nikolaos Pyrpyris, Kyriakos Dimitriadis, Konstantinos G. Kyriakoulis, Stergios Soulaidopoulos, Panagiotis Tsioufis, Aggelos Papanikolaou, Nikolaos G. Baikoussis, Alexios Antonopoulos, Konstantinos Aznaouridis, Konstantinos Tsioufis   +9 more
doaj   +2 more sources

A deep learning and molecular modeling approach to repurposing Cangrelor as a potential inhibitor of Nipah virus [PDF]

Scientific Reports
Deforestation, urbanization, and climate change have significantly increased the risk of zoonotic diseases. Nipah virus (NiV) of Paramyxoviridae family and Henipavirus genus is transmitted by Pteropus bats.
Levin John, Leona Dcunha, Mukhtar Ahmed, Sonet Daniel Thomas, Rajesh Raju, Abhithaj Jayanandan   +5 more
doaj   +2 more sources

Anti-Platelet Therapy with Cangrelor in Cardiogenic Shock Patients: A Systematic Review and Single-Arm Meta-Analysis [PDF]

Medicina
Background and Objectives: Percutaneous coronary intervention (PCI) is a proven therapy for acute myocardial infarction (AMI) cardiogenic shock (CS).
Jacopo D’Andria Ursoleo, Luca Baldetti, Marina Pieri, Pasquale Nardelli, Savino Altizio, Silvia Ajello, Anna Mara Scandroglio   +6 more
doaj   +2 more sources